Published in Thromb J on February 10, 2015
Thrombotest. A new method for controlling anticoagulant therapy. Lancet (1959) 8.34
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47
Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med (2013) 5.19
Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol (2011) 4.98
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb (2003) 4.44
Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care (2013) 3.65
Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood (1990) 3.38
Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost (2010) 3.03
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med (2013) 2.84
A specific antidote for dabigatran: functional and structural characterization. Blood (2013) 2.77
Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion (2005) 2.76
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost (2012) 2.61
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost (2010) 2.47
Thrombin generation and fibrin clot structure. Blood Rev (2007) 2.37
The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol (2003) 2.33
Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology (2012) 2.25
Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost (2012) 2.24
Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood (2010) 2.21
Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost (2006) 2.01
Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood (1999) 1.91
Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol (2012) 1.80
What is all that thrombin for? J Thromb Haemost (2003) 1.75
Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost (2013) 1.70
A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. Br J Haematol (2000) 1.70
Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost (2012) 1.70
DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost (2008) 1.60
Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem (2013) 1.58
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost (2010) 1.55
Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin Chem (2012) 1.54
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost (2011) 1.46
Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology (2014) 1.42
Thrombin generation: the functional role of alpha-2-macroglobulin and influence of developmental haemostasis. Br J Haematol (2007) 1.40
Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization. Am J Clin Pathol (2012) 1.39
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol (2013) 1.39
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov (2010) 1.33
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol (2010) 1.31
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost (2013) 1.25
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15
Kinetics of human factor VII activation. Biochemistry (1996) 1.13
The discovery of dicumarol and its sequels. Circulation (1959) 1.10
Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin. Thromb Res (2009) 1.05
Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA (1999) 1.05
The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost (2011) 1.05
Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res (2014) 1.05
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis (2011) 1.02
Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res (2007) 1.02
Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes (2012) 1.02
The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol (2012) 1.01
Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol (2012) 1.01
Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand (2005) 1.01
Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One (2013) 1.00
Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract (2008) 0.99
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost (2014) 0.98
International Committee for Standardization in Haematology, International Committee on Thrombosis and Haemostasis: ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost (1985) 0.97
Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost (2012) 0.97
The story of the discovery of heparin and warfarin. Br J Haematol (2008) 0.96
In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban. J Thromb Haemost (2013) 0.95
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. J Thromb Haemost (2014) 0.95
TEG® and ROTEM® in trauma: similar test but different results? World J Emerg Surg (2012) 0.95
Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost (2008) 0.94
History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation (1994) 0.94
Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clin Chem Lab Med (2014) 0.94
Determination of dabigatran in human plasma samples. Semin Thromb Hemost (2012) 0.93
The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin. J Thromb Haemost (2010) 0.92
Coagulation status using thromboelastography in patients receiving warfarin prophylaxis and epidural analgesia. J Clin Anesth (2002) 0.91
Plasma and cellular contributions to fibrin network formation, structure and stability. Haemophilia (2010) 0.91
Anticoagulants and the propagation phase of thrombin generation. PLoS One (2011) 0.89
Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med (2014) 0.89
Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system. Thromb Haemost (2011) 0.89
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis (2013) 0.89
Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res (1997) 0.87
Venous thrombosis and anticoagulant therapy. Br J Haematol (2001) 0.87
Disadvantages of VKA and requirements for novel anticoagulants. Best Pract Res Clin Haematol (2013) 0.87
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost (2013) 0.86
Has the time arrived to replace the quick prothrombin time test for monitoring oral anticoagulant therapy? Clin Chem (2005) 0.86
Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost (1998) 0.86
Data management in thrombin generation. Thromb Res (2012) 0.86
Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis (2011) 0.85
Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin (2012) 0.85
Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost (2013) 0.85
Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thromb Res (2014) 0.85
The role of prothrombin complex concentrates in reversal of target specific anticoagulants. Thromb J (2014) 0.85
Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. J Thromb Haemost (2006) 0.83
Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med (2012) 0.83
Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies. Thromb Res (2014) 0.82
Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. Thromb Res (2014) 0.82
Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography. Int J Cardiol (2014) 0.82
Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost (2014) 0.82
Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost (2014) 0.81
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost (2010) 0.81
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. J Thromb Haemost (2014) 0.81
HYPO-PROTHROMBINEMIA PRODUCED BY 3,3-METHYLENEBIS (4-HYDROXYCOUMARIN) AND ITS USE IN THE TREATMENT OF THROMBOSIS. Science (1942) 0.81
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett (2009) 0.81
Effect of warfarin on the activated partial thromboplastin time. Drug Intell Clin Pharm (1986) 0.79
Disagreement between bedside and laboratory activated partial thromboplastin time and international normalized ratio for various novel anticoagulants. Blood Coagul Fibrinolysis (2001) 0.79
Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thromb Haemost (2001) 0.78
Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. J Thromb Haemost (2013) 0.78
TEG® and RapidTEG® are unreliable for detecting warfarin-coagulopathy: a prospective cohort study. Thromb J (2014) 0.77